Big biopharma deals make 2015 most lucrative first quarter for M&A since 2009
In the first quarter of 2015, the pharma, medical and biotech industry saw 79 merger and acquisition deals worth $72.9 billion, according to a new report by Mergermarket.
After a record year in 2014, the first quarter’s figures of deals totaling $90.8 billion represented a 64.4% increase on the same period last year, which was $55.3 billion. The first quarter of 2015 is now the second highest-valued first quarter on record, after 2009. The year-on-year increase from 2014 to 2015 was driven by particularly strong activity in pharma, which had a 117.8% increase by value with 15 more announcements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze